BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11823970)

  • 21. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
    Hoff ER; Tubbs RR; Myles JL; Procop GW
    Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization.
    Ooi A; Kobayashi M; Mai M; Nakanishi I
    Lab Invest; 1998 Mar; 78(3):345-51. PubMed ID: 9520947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use.
    Bánkfalvi A; Simon R; Brandt B; Bürger H; Vollmer I; Dockhorn-Dworniczak B; Lellé RJ; Boecker W
    Histopathology; 2000 Nov; 37(5):411-9. PubMed ID: 11119122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification.
    Horimoto Y; Terao T; Tsutsumi Y; Tanabe M; Mogushi K; Hlaing MT; Sasaki R; Saeki H; Okazaki M; Sonoue H; Arakawa A; Saito M
    Am J Surg Pathol; 2019 Sep; 43(9):1221-1228. PubMed ID: 31192864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.
    Tsuda H; Iwaya K; Fukutomi T; Hirohashi S
    Jpn J Cancer Res; 1993 Apr; 84(4):394-401. PubMed ID: 8099903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype.
    Fiche M; Avet-Loiseau H; Heymann MF; Moussaly F; Digabel C; Joubert M; Classe JM; Dravet F; Fumoleau P; Ross J; Maugard CM
    Int J Cancer; 1999 Oct; 84(5):511-5. PubMed ID: 10502729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
    Bhargava R; Lal P; Chen B
    Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
    Lebeau A; Deimling D; Kaltz C; Sendelhofert A; Iff A; Luthardt B; Untch M; Löhrs U
    J Clin Oncol; 2001 Jan; 19(2):354-63. PubMed ID: 11208826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.
    Lal P; Salazar PA; Ladanyi M; Chen B
    J Mol Diagn; 2003 Aug; 5(3):155-9. PubMed ID: 12876205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
    Somerville JE; Clarke LA; Biggart JD
    J Clin Pathol; 1992 Jan; 45(1):16-20. PubMed ID: 1346789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
    Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M; Kodet R; Kalinová M; Hilská I
    Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
    Mrhalova M; Kodet R
    Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.
    Hoang MP; Sahin AA; Ordòñez NG; Sneige N
    Am J Clin Pathol; 2000 Jun; 113(6):852-9. PubMed ID: 10874886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.